Abstract | The molecular biology revolution coupled with the development of monoclonal antibody technology enabled remarkable progress in rheumatology therapy, comprising an array of highly effective biologic agents. With advances in understanding of the molecular nature of immune cell receptors came elucidation of intracellular signalling pathways downstream of these receptors. These discoveries raise the question of whether selective targeting of key intracellular factors with small molecules would add to the rheumatologic armamentarium. In this Review, we discuss several examples of this therapeutic strategy that seem to be successful, and consider their implications for the future of immune-targeted treatments. We focus on kinase inhibitors, primarily those targeting Janus kinase family members and spleen tyrosine kinase, given their advanced status in clinical development and application. We also summarize other targets involved in signalling pathways that might offer promise for therapeutic intervention in the future.
Introduction
Rheumatoid arthritis (RA) is a disease manifested by inflammatory synovitis, articular destruction and wider comorbidity, including effects in the vasculature, bone, lungs and brain. This pathology leads to progressive disability and adverse social cost to individuals with the disease and to the wider health-care economy. Recent therapeutic advances, built on aggressive use of conventional and biologic disease-modifying agents coupled with considerable evolution of our treatment strategies, have substantially improved outcomes in RA; however, unmet needs remain, manifest mainly in partial or nonresponses-few patients achieve sustained remission.
A brief history of the therapy of RA Pharmaceutical compounds, drawn from a broad range of chemical classes, have long formed the core of therapy for RA. Emanating from the original discovery of aspirin, the NSAID class has been widely used in RA, underpinned by superb biochemistry, culminating in the advent of cyclooxygenase 2 (COX-2)-selective agents. These agents, however, do not achieve true disease modification in that symptoms are improved but the underlying joint destruction is not halted. Furthermore, long-term use of NSAIDs is limited by gastric and renal toxicity associated with these agents. Glucocorticoids probably represent the most remarkable historic advance in the treatment of inflammatory disease. Because of the diverse functions of the glucocorticoid receptor, these agents have potent anti-inflammatory and immunemodifying effects, and are disease-modifying in RA. However, the ubiquitous receptor biology that contributes to the therapeutic activity of glucocorticoids also results in adverse effects, which affect many systems in the body, limiting the long-term use of these agents. The mainstay of RA therapeutics has been conventional DMARDs, comprising a group of agents assembled serendipitously from other disciplines, such as methotrexate, sulphasalazine, hydroxychloroquine and azathioprine. The precise, 'disease relevant' mechanisms of action of these compounds remain elusive and, importantly, their introduction was not directed by a rationaliza tion of target biology related to RA patho genesis. Moreover, conventional DMARDs do not specifically target immune cells. Similarly, other immuno modulatory drugs, often modulators of intracellular targets that are typically ubiquitous, have been discovered empirically. Despite the fact that these agents are not specifically 'targeted therapies' , they are clearly efficacious in the treatment of RA.
The huge advances in molecular biology and biochemistry during the past 20 years has given us a detailed understanding of the structure and function of dozens of key receptors expressed on immune cells, ranging from the T-cell, B-cell and Fc receptors to co-stimulatory molecules; our understanding of the biochemistry of immune cell activation now is vastly more sophisticated. Molecular cloning has also revealed a remarkable array of cytokines that control the growth and differentiation of hematopoietic cells, as well as orchestrate virtually all aspects of development and resolution of immune responses. Furthermore, molecular biology tools have permitted the production of recombinant cytokines and cytokine receptors. At the same time, monoclonal antibody technology enabled the generation of therapeutic antibodies. This advance facilitated the introduction of, initially, biologic TNF-blocking agents that markedly improved outcomes in RA and, subsequently, a range of other effective biologic agents targeting several cytokines and receptors expressed on immune cells.
Looking to the future Advances in the understanding of receptor biology and signal transduction pathways have raised important new questions: knowing what we know about immune cell signalling, can we target intracellular pathways used by the key immunoreceptors that trigger inflammatory responses to generate new drugs that work when others do not? Moreover, by selecting signalling molecules that operate as critical nodes in these pathways, can we achieve a higher magnitude or more robust duration of response? We now know that not only are kinases key nodes, but they are also excellent targets for new drugs. In this Review, we therefore focus on kinases that form the basis for new, targeted therapies.
Kinases and immune cell signalling
Elegant work in multiple systems established that reversible phosphorylation is a major mechanism for regulation of protein function in all eukaryotic cells. The enzymes that mediate this modification are termed phosphotransferases or kinases. Thanks to completion of human genome sequencing projects, we now know that a total of 518 kinases comprise the human 'kinome' . Some receptors, such as the insulin receptor and epidermal growth factor receptor, are themselves kinases, whereas other receptors directly interact with intracellular kinases. Thus, many fundamental receptor-meditated processes, including cell growth and differentiation, are regulated by phosphorylation. Similarly, many key immune receptors, including those responsible for driving inflammation, exert their effect through kinases. One might imagine Key points ■ Biologic agents have revolutionized the therapy of rheumatoid arthritis (RA); nevertheless, not all patients achieve remission and many exhibit only partial responses ■ Advances in our understanding of signal transduction by key immunological receptors offer numerous opportunities for devising new oral, targeted therapies ■ >60 cytokines signal via the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways; genetic evidence has established that these factors are essential to cytokine signalling ■ JAK inhibitors (jakinibs) have now been approved for the treatment of RA and other diseases, and various jakinibs are being developed and tested in a range of autoimmune diseases ■ Spleen tyrosine kinase (SYK) and Bruton tyrosine kinase (BTK) are critical kinases downstream of key immunological receptors; inhibitors of these proteins are being tested in RA and other diseases ■ The human kinome comprises 518 kinases; therefore, no shortage of potential new therapeutic targets exists the prospect of developing kinase-specific inhibitors as therapeutic agents would be chemically challenging. Most successful inhibitors bind the highly conserved catalytic site of these enzymes that binds ATP. Nevertheless, we know that kinases are useful targets for the generation of new drugs, with proof-of-concept provided originally in the field of oncology. In fact, existing FDA-approved kinase inhibitors have a range of selectivity: none are completely specific for a single kinase and some are actually rather broad in the range of kinases they inhibit. The elucidation of the mammalian kinome is relevant in this regard. The targeted deletion of individual kinases in mice has given us insights into which enzymes have broad and/or essential activities, and thus should not be targeted for therapeutic intervention. Although the array of kinases that could be targeted in rheumatic disease is large, the first, seemingly successfully, targeted candidates are those that function downstream of cytokine, antigen and Fc receptors.
Targeting type I/II cytokine receptors
Cytokines that bind type I and type II cytokine receptors comprise a range of factors including interleukins, interferons and colony-stimulating factors, as well as hormone-like cytokines (erythropoietin, prolactin, growth hormone and leptin). These receptors all exert their effects through the activation of Janus kinases (JAKs). The intracellular domains of these receptors selective bind to the different JAKs-tyrosine kinase 2 (TYK2), JAK1, JAK2 and JAK3-in various combinations (Figures 1 and 2 ). JAK1 and JAK2 are broadly used by many different cytokines, whereas JAK3 has more limited function, associating with cytokine receptor common subunit γ (γ c , also known as CD132). The essential function of JAKs in cytokine signalling is demon strated by clear genetic data. 1 Loss-of-function mutations of JAK3 and TYK2 profoundly inhibit immune responses in both mice and humans. 1 Loss-of-function mutations of JAK1 and JAK2 have not been identified in humans; however, the kinases encoded by these genes have profound effects, as evident in knockout mice, in which germline deletion of either of these proteins is lethal and signalling by multiple cytokines is abrogated.
1,2
Janus kinase inhibitors in autoimmune disease The first selective JAK inhibitor (jakinib) to be tested in humans was tofacitinib (formerly designated CP-690,550). Tofacitinib inhibits JAK1, JAK3 ( Figure 2 ) and, to a lesser extent, JAK2; 3 this compound has limited effect on TYK2 and on kinases other than JAKs. 4 Tofacitinib was found to be efficacious in a variety of preclinical models ranging from transplant to arthritis models. 3, 5 The efficacy of this inhibitor in human disease has been investigated in multiple clinical trials in RA, [6] [7] [8] [9] [10] [11] inflammatory bowel disease, 12 psoriasis 13 and renal transplantation (Table 1) . 14 In the treatment of RA in particular, tofacitinib exhibits comparable efficacy to adalimumab and methotrexate. 15 Of particular importance, tofacitinib was found to be efficacious in patients who had failed to respond to therapy with multiple biologic agents. 15 Evidence suggests that tofacitinib therapy prevents structural damage; 16 however, this finding will need to be confirmed and, in particular, the optimal dose to achieve this outcome needs to be established. On the basis of these findings, this drug has been recommended for approval for the treatment of moderate-to-severe RA in patients who have failed to respond to other disease-modifying drugs. Encouraging early efficacy is emerging in studies in psoriasis 13 and ulcerative colitis, 12 indicating broad disease applicability of this mechanism-based approach to kinase inhibition.
Although one might assume, on the basis of mouse knockout data, 1 that inhibition of JAK2 would be problematic, the discovery that gain-of-function JAK2 mutations underlie the myeloproliferative disorders provided a rationale for purposefully targeting this kinase. 17 One such inhibitor, ruxolitinib (INCB18424), which inhibits JAK1 ( Figure 2 ) and JAK2, is efficacious in the setting, 18, 19 but has also been studied in RA. 20 Similarly, baricitinib (formerly INCB28050 or LY3009104) is also an inhibitor of both JAK1 ( Figure 2 ) and JAK2 and has showed efficacy in a phase II trial in RA. [21] [22] [23] Extended studies of these compounds (and other jakinibs) in autoimmune diseases and also in cancer are ongoing (Table 1) . 3,4 To a lesser extent, tofacitinib inhibits JAK2 and, therefore, interrupts IL-12 and IL-23 (as well as the cytokine receptor common subunit β [β c ] family cytokines IL-3, IL-5 and granulocyte-macrophage colony-stimulating factor). 3, 24 As a result, tofacitinib has potent effects on lymphocytes: it blocks differentiation of type 1 T helper (T H 1) cells and type 2 T helper (T H 2) cells, and interferes with the generation of pathogenic type 17 T helper (T H 17) cells. 3 Tofacitinib seems to have a limited effect on lymphocyte numbers in humans; however, populations of natural killer (NK) cells and CD8 + T cells declined in nonhuman primates follow ing exposure to this agent. 25, 26 Whether alterations in NK cell number will be an issue in humans treated with tofacitinib remains unknown. Furthermore, formal definition of the functional impact of tofacitinib on lympho cyte subsets in patients is required to enable more precise characterization of the relevant mode of action of this compound in RA; it is hoped that this information will, in turn, enable optimization of next-generation selective jakinibs.
First-generation jakinibs-mechanism of action
Tofacitinib also blocks JAK1 (Figure 2 ), which has a vital role in signalling by γ c family cytokines and is also critical for membrane glycoprotein 130 (gp130)-using cytokines and interferons. Cytokines that signal through gp130 are especially relevant to RA. That is, IL-6-a molecule known to participate in the pathogenesis of RA-signals through a receptor containing this protein; consequently, tofacitinib can block innate immune responses. In a mouse model of established arthritis, tofacitinib blocked the production of proinflammatory cytokines and macrophage activation, and attenuated TNF-driven responses. 3 Tofacitinib also blocked the effects of cytokines on synovial fibroblasts, inhibiting chemokine expression. 27 Moreover, in a rat model of RA, tofacitinib reduced RANKL production, and, by this means, limited structural damage. 28 As ruxolitinib and baricitinib inhibit JAK1 ( Figure 2 ) and JAK2, they can interrupt signalling downstream of the same cytokines as tofacitinib, despite having limited activity on JAK3. Deletion of JAK3 (or Jak3 in mice) blocks lymphocyte development because of the requisite role in γ c signalling of the kinase encoded by this gene. [29] [30] [31] [32] However, gene targeting of Jak1 also results in a severe combined immunodeficiency phenotype, 33 as JAK1 is also required for signalling by γ c family cytokines JAK3 is thought to associate uniquely with γ c , the shared subunit of the cytokine receptors used by IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. Inhibition of JAK3, therefore, blocks signalling by these cytokines. γ c cytokines also utilize JAK1, so agents that inhibit JAK1 will also block signalling by these cytokines. In contrast to JAK3, JAK1 is also used by a number of other cytokines: those that signal via gp130; IFNs; and IL-10-family cytokines. Similar to JAK1, JAK2 is important for signalling by an array of cytokines including IFN-γ, IL-6, and other cytokines. JAK2 is important for signalling by IL-3, IL-5 and GM-CSF, and is essential for signalling by EPO, TPO and growth hormone. Therefore, inhibitors that block both JAK1 and JAK2 interfere not only with signalling by many proinflammatory cytokines, but also with EPO signalling and thus can cause anaemia. TYK2 also contributes to IL-6 and IL-10 signalling and is especially important for the actions of IFN-α and IFN-β. At present, there are no TYK2 inhibitors in clinical use. Abbreviations: β c , cytokine receptor common subunit β; EPO, erythropoietin; γ c , cytokine receptor common subunit γ; GM-CSF, granulocyte-macrophage colonystimulating factor; IFN, interferon; JAK, Janus kinase; jakinibs, JAK inhibitors; LIF, leukaemia inhibitory factor; OSM, oncostatin-M; TPO, thrombopoietin; TYK2, tyrosine kinase 2.
insofar as this enzyme is an obligate partner for JAK3 at these receptors. This perspective explains the expectation that these three drugs might have similar overall mechanisms of action and effects, in terms of the cytokines that are blocked. However, the extent and duration of inhibition of JAK family members are likely to differ between the three agents.
Adverse events associated with jakinibs
The most common, clinically relevant adverse event associated with jakinib treatment is infection. Infections associated with these agents include upper respiratory and various other infections, and also opportunistic infections such as Mycobacterium tuberculosis and Herpes zoster. [7] [8] [9] [10] 12, 15 Patients treated with jakinibs can also develop anaemia, leukopenia and thrombocytopenia;
7-10,12,15 these conditions probably result from interference with signalling by erythropoietin and other colony-stimulating factors, which rely on JAK2 for their action. An unexpected adverse effect of jakinibs is hyperlipidaemia, [7] [8] [9] [10] 12, 15 perhaps reflecting direct effects on cholesterol metabolism, which is itself dysregulated in the context of chronic inflammatory diseases. Indeed, other immune modulators are also associated with altered lipid profiles. This effect perhaps reflects the evolutionary integration of regulatory mechanisms for metabolic and immune processes.
The future of jakinibs in autoimmune diseases Obviously, we are just beginning the era of therapeutic JAK inhibition in the treatment of RA and inflammatory bowel disease. Biologic agents have raised the bar in the treatment of autoimmune disease, given that they are effective and safe. As tofacitinib is now, and should other jakinibs be, approved for these indications, how clinicians deploy these agents is of great interest. The fact that jakinibs are oral agents is likely to be seen as advantageous. As a substantial proportion of patients do not respond to biologic therapies, this is the setting in which jakinibs will probably be used. A case for intervention with jakinibs earlier in the RA treatment paradigm might emerge with the increasing presentation of safety datasets for these agents. The question also arises whether ja kinibs will be useful in other clinical settings. Clinical trials in other arthritides and other diseases are underway and preclinical data suggest that jakinibs might be useful in the treatment of systemic lupus erythematosus (SLE). [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] The ability of jakinibs to block cytokines involved in the pathogenesis of SLE (type I interferons, IL-6, IL-21, etc.) makes them potentially attractive. As prototypic T H 2-cell-mediated diseases, severe asthma and allergies could represent another setting in which jakinibs, especially in topical formulations, might be of use; the potential utility of these agents has already been established in preclinical models. 44 An obvious further question is to what extent jakinibs will be generally useful as steroid-sparing or steroid-replacing agents across an even wider range of inflammatory diseases.
The jakinibs available at present inhibit multiple JAKs; however, the development of more selective second-generation agents is underway. VX-509 is reportedly more specific for JAK3 than the other JAKs (Figure 2) . 45 This compound has also shown efficacy in a phase IIa study in patients with RA (Table 1) . 46, 47 Of interest, a reportedly selective JAK1 inhibitor, GLPG0634 (Figure 2) , has also showed efficacy in a phase II trial in RA (Table 1) . 48, 49 Assessment of the relative merits of inhibiting the various JAKs in different clinical settings will be of great interest, particularly in balancing safety and efficacy. However, although one might assume that more selectivity would be better, this assumption is not always borne out; consider the experience with NSAIDS and selective COX-2 inhibitors. Fc receptors (FcRs), are structurally related. These receptors are complexes comprising ligand-binding subunits associated with signalling subunits and are thus referred to as multichain immune recognition receptors, a family that includes not only the TCR, BCR and FcRs, but also many other important receptors. Importantly, all these receptors are linked to protein tyrosine kinases, and tyrosine phosphorylation of the receptor itself is the first step in receptor-mediated signalling (Figure 3) . [50] [51] [52] [53] [54] Receptor phosphorylation is mediated by Src family protein tyrosine kinases. Phosphorylation of a given receptor on speci fic tyrosine residues (referred to as immuno receptor tyrosine based activation motifs [ITAMs]) leads to the recruitment of spleen tyrosine kinase (SYK) and/or 70 kDa ζ-chain associated protein (ZAP-70) by virtue of tandem Src homology 2 domains. Subsequently, another class of tyrosine kinases are activated, the plextrin-homology-domain-containing kinases; Bruton tyrosine kinase (BTK) is one such kinase. Although clinically useful SYK and BTK inhibitors have been developed, no Src family inhibitors have yet emerged as successful drugs in the clinic.
Targeting B-cell and Fc Receptors

SYK and BTK inhibitors
SYK inhibitors SYK and ZAP-70 make up a small, structurally distinct kinase family, and both proteins are involved in antigen receptor signalling. ZAP-70 functions immediately downstream of the TCR, 51, 55 whereas SYK is minimally expressed in T cells. Patients who lack ZAP-70 have a severe combined immunodeficiency characterized by lymphopenia. 56 Despite the obvious importance of ZAP-70 to T-cell function and thus various diseases, a selective, clinically useful inhibitor of this kinase has yet to be developed.
SYK plays an analogous part to ZAP-70 in BCR signalling, binding the phosphorylated intracellular domains of the B-cell antigen receptor (Figure 3) , 57 and also has a similar critical role downstream of FcRs. 54 In addition, SYK has other functions, including mediating integrin signalling. 58 Indicative of its multiple and wideranging functions, SYK-deficient mice die in the perinatal period with fatal haemorrhage due to abnormal formation of blood vessels and the lymphatic system. Mice transplanted with SYK-deficient bone-marrowderived cells have near normal T-cell development but fail to develop mature B cells, suggesting that this kinase could be a useful therapeutic target. 59, 60 A SYK inhibitor, fostamatinib (R788), has shown efficacy in preclinical models of RA, 61 and has been tested in clinical trials in patients with RA. 62, 63 Phase II trials of fostamatinib in indivi duals with moderate-to-severe RA yielded mixed results: patients with prior inadequate res ponse to methotrexate exhibited satisfactory responses, 62 whereas those previously treated unsuccessfully with TNF inhibitors did not seem to benefit. 63 Trial design issues beset the latter study and the results of larger, phase III studies are now awaited to properly define the potential of this inhibitor, and indeed the SYK pathway, in the RA therapeut ic armamentarium.
Given the breadth of actions of SYK in B cells, myeloid cells and other cells, defining the precise therapeutic mechanism of action of a SYK inhibitor such as fostamatinib in RA is challenging. The drug certainly interferes with B-cell activation (Figure 3) , and, in fact, short-term use of fostamatinib has been reported to impair B-cell development at the transitional stage, without affecting mature B-cell populations; 64 however, in addition to these effects on B cells, important aspects of the drug's efficacy probably relate to its modulation of the activity of myeloid and other cell types, particularly mast cells and neutrophils and perhaps also osteoclasts.
Adverse effects of fostamatinib treatment include neutropenia, transaminitis and hypertension. 62 The mechanism underlying fostamatinib-associated hypertension is somewhat elusive at present; however, given the broad roles of SYK and, in particularly, its role in vascular development, 59 ,60 this effect of fostamatinib could be related to SYK inhibition. Alternatively, fostamatinib could inhibit kinases other than SYK such as vascular endothelial growth factor receptor. Indeed, now that surveying the effect of any given drug on the kinome is relatively straightforward, the expectation that rheumatolo gists know what spectrum of kinases a particular compound is inhibiting is fair. As with jakinibs, whether greater selectivity of SYK inhibitors 
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is necessarily advantageous remains unclear; indeed, a broad-spectrum inhibitor might be beneficial in some circumstances. Phase III studies of fostamatinib in RA are currently underway. 65 Given the importance of SYK for BCR and FcR signalling, SLE represents a further setting in which use of a SYK inhibitor could be of therapeutic benefit. In fact, fostamatinib has shown efficacy in mouse models of lupus. 66, 67 The other obvious setting in which SYK inhibitors might have utility is in B-cell malignancies. 68 
BTK inhibitors
After activation of Src family kinases and SYK or ZAP-70, a third, structurally distinct class of tyrosine kinases, known as the plextrin homology (PH) domaincontaining kinases, are recruited to the antigen receptor signalling complex (Figure 3) . 69 This third group, also referred to as the Tec family of kinases, includes IL-2-inducible T-cell kinase (ITK, also known as Lyk), resting lymphocyte kinase (RLK, also known as TXK), BTK, BMX and Tec. The primary immunodeficiency, Bruton agammaglobulinaemia (also called X-linked agammaglobulinaemia), is caused by mutations of the eponymous kinase-BTK. Mutations in Btk in mice or BTK in humans abrogate B-cell development, resulting in a lack of mature B cells. 70, 71 BTK is essential for signal transduction downstream of the BCR and also has a role in Toll-like receptor and FcR signalling in myeloid cells. BTK-deficient dendritic cells have impaired secretion of inflammatory cytokines and BTK-deficient mast cells demonstrate impaired degranulation in res ponse to FcR activation. 72, 73 By contrast, T cells are unaffected by loss of BTK and BTK-deficient patients can live essentially normal lives providing they receive regular transfusions of immunoglobulin. This finding can be explained by the fact that other PH-domain-containing kinases including Tec, ITK and RLK are expressed in T cells; indeed, mice lacking combinations of these three kinases have T cells with varying degrees of functional impairment. 69 The robust and discrete genetic phenotype associated with BTK deficiency make this kinase a logical pharmacological target (Figure 3) . The BTK inhibitor PCI-32765 has efficacy in animal models of arthritis and, as expected, acts on multiple effector cell types. 74, 75 This drug is currently in phase II clinical trials for the treatment of B-cell lymphomas, including myeloma and chronic lymphocytic leukaemia; however, given the success of B-cell-directed therapy in RA, targeting BTK in RA would seem logical. Whether the absence of T-cell-mediated effects will diminish the potential for beneficial effects of this agent in RA is currently unclear.
Targeting downsteam kinases
After activation of the kinases proximal to antigen and Fc receptors, other important kinases are also activated. Such downstream kinases include members of the protein kinase C (PKC) family, mitogen-activated protein kinase (MAPK) family, the lipid kinase phosphoinositide 3-kinase (PI3K), protein kinase B (PKB, also known as AKT) and mammalian target of rapamycin (mTOR) (Figure 2 and Figure 3) .
The protein kinase C family One of the first-defined antigen-receptor-controlled signal transduction pathways involved phospholipase C-γ-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate. This process results in the production of inositol 1,4,5 trisphosphate (IP 3 ) and diacylglycerol, which regulate intracellular calcium levels and activate a number of diacylglycerol-activated serine/threonine kinases, respectively (Figure 3) . 57, [76] [77] [78] Prominent among the diacylglycerol-activated kinases are the members of the PKC family. One effector component of the PKC pathway in lymphocytes is activation of nuclear factor κB (NFκB) signalling. 79 PKCθ seems to be the main isoform responsible for NFκB activation in T cells. 80 The PKC inhibitor sotrastaurin (AEB071), which inhibits α, β, and θ PKC isoforms, is currently undergoing clinical trials in psoriasis and renal transplantation. [80] [81] [82] On the basis of its mode of action, the hypothesis that this drug could have efficacy in other autoimmune diseases seems reasonable.
PI3K, PKB and mTOR
Cytokines, antigen receptors, co-stimulatory molecules and chemokines can all induce tyrosine phosphorylation of substrates that activate another kinase, PI3K. This enzyme generates the active lipids phos phatidylinositol (3,4)-bisphosphate (PIP 2 ) and phos phatidylinositol (3,4,5)-trisphosphate (PIP 3 ), which activate PKB (Figure 2) . [83] [84] [85] This pathway is important for the uptake of nutrients and the regulation of glucose metabolism by glycolysis. [86] [87] [88] PI3K-PKB signalling has functions far beyond its roles in immune cells and is commonly deregulated in human tumours, 89, 90 which have made this pathway a prime target for the development of smallmolecule inhibitors for the treatment of cancer. Whether such drugs have a useful immunosuppressive function within an acceptable safety window remains to be seen.
Another serine/threonine kinase downstream of PI3K is mTOR (Figure 2 ), which regulates protein synthesis in response to cellular nutrient and energy levels. 91 mTOR is activated by cytokines, as well as by many other factors. The importance of mTOR is underlined by the conservation of this protein from yeast to mammals. At this juncture, it might seem odd to purposefully target a kinase that is ubiquitously expressed in all eukaryotes; however, rapamycin was generated and developed empirically in 1975, long before the elucidation of immune-cell signalling pathways. As the name suggests, mTOR is inhibited by the macrolide rapamycin, now licensed for the treatment of graft rejection as sirolimus. Sirolimus does not inhibit mTOR directly by binding within the ATP-binding pocket, as do the other inhibitors discussed thus far; rather, it acts indirectly, associating with 12kDa FK506 binding protein (FKBP12). In view of the ubiquitous expression of mTOR and the role of this kinase in protein translation, sirolimus use is unsurprisingly associated with varied adverse effects including hyperlipidaemia, hypertrigliceridaemia, myelosuppression and delayed wound healing. 92 Nevertheless, sirolimus has less renal toxicity than calcineurin inhibitors, making it an attractive agent in allograft prophylaxis. Currently, three rapamycin derivatives are undergoing clinical trials, namely temsirolim us, everolimus and AP23573. 93 The mitogen-activated protein kinase family The MAPK family constitutes a complex phosphorelay system of signal transduction, composed of three sequentially activated kinases that are themselves modulated by phosphorylation. 94, 95 The top-level kinases in the three-tiered pathway are termed MAPK kinase kinases (MAPKKKs or MKKKs) and activate the middle level MAPK kinases (MAPKKs or MKKs), which subsequently activate the lowest tier kinases, comprising the MAPKs. Similar to the mTOR pathway, MAPKs are also conserved within eukaryotes. The three main MAPK cascades in mammalian cells involve the MAPKs extracellular signal-regulated kinase (ERK) 1 and/or ERK2, c-Jun N-terminal kinase (JNK) 1 and/or JNK2, and p38 MAPK. All of these cascades are activated in lymphocytes and antigen-presenting cells downstream of ligand-binding to antigen receptors, co-stimulatory and adhesion molecules or cytokine receptors. The differential functions of the MAPKs enables fine-tuning of cell responses to exogenous stress, cytokines and other immune-receptor stimuli.
The ERK1/2 cascade is ubiquitous in mammalian cells and is a principal effector pathway regulated by the Ras GTPases and the MKKK Raf (Figure 3 ). This pathway is activated in both immune cells and cancer cells. The kinase inhibitor sorafenib is able to inhibit many kinases, including Raf, and is approved by the FDA for the treatment of liver and renal cell cancers. 96 Sorafenib is generally well tolerated despite its ability to inhibit numerous kinases. The role of this agent as an immunosuppressant has not been explored, although sorafenib use is associated with the development of posterior encephalopathy syndrome, 97 a side effect typically associated with the use of calcineurin inhibitors and other immunosuppressant drugs. 98 Other Raf inhibitors are under development, at present. In addition, selective inhibitors of ERK MAPKs are being developed: the ERK2 inhibitor FR180204 has been shown to inhibit the development of collagen-induce arthritis in mice and is being considered as a therapeutic agent in the treatment of RA. 99 JNKs are activated by multiple receptors including the TCR, co-stimulatory molecules and the TNF receptor. Mouse CD4 + T cells deficient in JNK1 or JNK2 have impaired T H 1 polarization. [100] [101] [102] In CD8 + T cells the JNK proteins have contrasting roles: JNK1-deficient CD8 + T cells have impaired proliferation and cytokine production, whereas JNK2-deficient CD8 + T cells have elevated cytokine expression. 103, 104 Importantly, the JNK pathway has a critical role in TNF and IL-1 signalling. [105] [106] [107] A number of small-molecule inhibitors of JNKs have been identified and are currently being investigated in animal models of autoimmune and inflammatory disease. 108 The third limb of the MAPK superfamily is the p38 MAPK cascade, which was identified as part of a drug screen specifically intended to find inhibitors of TNFmediated inflammatory responses. 109 Although many p38 MAPK inhibitors have been reported, their development into therapeutic drugs has been frustrated by either unacceptable toxicity (AMG 548, BIRB 796) or poor efficacy (SCIO-469, VX-702). 110 Nonetheless, investigation of the therapeutic potential of p38 inhibition continues. 111 Although, in principle, p38 inhibitors would be expected to be excellent anti-inflammatory drugs, the future of this approach is uncertain. 112 
Conclusions
The effectiveness of biologic therapies in rheumatoid diseases has been remarkable; however, there are now some new kids on the block that are clearly important to consider. With the recent licensing of tofacitinib for use in RA, oral targeted therapies are now a reality, but rheumatologists will need to consider how they will use these agents in their practice. Rheumatologists will have to develop an understanding of how these drugs work, of the selectivity of the agents and whether selectivity is beneficial or not. With hundreds of potential kinases to target, this is a field that is likely to expand considerably; rheumatologists are going to have to dust off their biochemistry textbooks! In the field of kinase inhibitors, much activity comes from oncology. There is a sense in which we are going back to the future, as rheumatologists have a long history of borrowing drugs from oncologists; one might imagine a range of such agents will have utility in autoimmune disease. The good news is that we are in exciting times-in addition to effective biologic agents, a number of highly effective oral drugs seem to be on the horizon.
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